Kintor Pharmaceutical (China) is unquestionably the true deal. They’re transferring quicker than every other firm within the historical past of the hair loss business. I believe all long-time weblog readers will agree. Furthermore, they’re conducting hair loss trials for 2 separate androgen receptor merchandise, and that too in two international locations. For each women and men.
25 yrs after Finasteride accredited, DHT is changed by Androgen Receptor as no. 1 enemy of hair.
1) Kintor (AR antagonist KX-826 Section 3; AR degrader GT20029 Section 2).
2) Cosmo (AR inhibitor Breezula Section 3).
3) OliX (OLX104C Section 1).
4) CosmeRNA (AR reducer beauty out quickly).— HairLossCure2020 (@HLcure2020) November 24, 2022
Replace: December 1, 2022
Kintor Section 2 Outcomes for KX-826 in Females
Not surprisingly, one more constructive Kintor replace. Their Pyrilutamide (KX-826) section 2 scientific trial outcomes for females with androgenetic alopecia simply received launched. And the findings are constructive. Complete space hair depend (TAHC) elevated 11.39 hairs per cm2 in contrast with the placebo group after24 weeks of therapy. It looks as if they’re going with a dosage of KX-826 5mg (0.5%) as soon as a day, though twice a day was additionally examined.
The general security profile of Pyrilutamide in females was good, and no participant wanted to drop out because of any opposed occasion. Notice that these outcomes, while encouraging, are lower than half what was seen in males (22.73 hairs per cm2 improve). See additional beneath for the prior updates on the male trials. Each these Section 2 trial have been performed in China, and Kintor is epxected to conduct Section 3 trials for males an ladies in China too.
Replace: November 24, 2022
Section 1 Trials for GT2009 a Success
Kintor’s simply introduced constructive top-line outcomes for its Section I scientific trial of GT20029 for the therapy of androgenetic alopecia (AGA) and zits. GT20029 is the world’s first t1opical Proteolysis Concentrating on Chimera (PROTAC) compound that has accomplished Section I scientific trials. It really works by degrading the androgen receptor (AR). The topical administration of GT20029 was secure and well-tolerated, with restricted systemic publicity.
Replace: August 29, 2022
Kintor Releases KX-826 Section 2 Trial Ends in Males
Kintor simply launched the Section 2 outcomes from China on their web site and they’re constructive. Notice that this Pyrilutamide (KX-826) topical hair loss product is an androgen receptor antagonist. In distinction, present hair loss merchandise Finasteride and Dutasteride are each oral DHT inhibitors.
Key quote:
“The outcomes confirmed that the KX-826 (0.5%) 5mg BID group demonstrated important enchancment in TAHC as in contrast with the baseline (elevated by 22.73 hairs per cm2; and placebo group (elevated by 15.34 hairs per cm2) after 24 weeks of therapy. The advocate section III dose is set as KX-826 (0.5%) 5mg BID.”
Notice that BID means twice every day. A complete of 120 Chinese language grownup male topics with a imply age of 35.6 have been enrolled within the research. All had a Hamilton-Norwood classification III or increased balding sample. They have been equally divided into 4 teams:
- KX-826 2.5 mg (0.25% focus) twice every day.
- KX-826 5 mg (0.5% focus) as soon as every day.
- KX-826 5 mg (0.5% focus) twice every day.
- Placebo.
The general security profile of KX-826 was good per these outcomes. No critical opposed occasion (SAE), opposed drug response (ADR), or dying occurred. After 14 days of topical utility, the blood focus of KX-826 was very low in all dose teams.
Kintor says that it’ll speed up the scientific progress of KX-826 and GT20029 with a purpose to:
“Carry extra modern and efficient therapy choices to the a whole bunch of tens of millions of individuals affected by AGA and zits vulgaris worldwide.”
Replace: August 11, 2022
Pyrilutamide Section 2 Scientific Trial Outcomes
Nice information per a Chinese language contact. It seems like Kintor could lastly current the outcomes of its Section 2 Chinese language trials of Pyrilutamide (KX-826) for hair loss on September 3 at 8:20 pm . The presenter can be Dr. Zhou Cheng from Peking College Folks’s Hospital (the place Kintor’s Section 3 trials are additionally being performed proper now).
Notice that Kintor is not named within the presentation. Nonetheless, I observed that the chairman of this group of presenters (from Peking College) is Dr. Zhang Jianzhong. This man is listed in Kintor’s press releases because the principal investigator! So I made a decision to replace this submit because it seems plausible now after months of ready and delays.
The doable presentation (after translation) is titled: “New progress in analysis and therapy of androgenetic alopecia.” Please observe that this KX-826 androgen receptor antagonist product is unlikely to carry again lengthy misplaced hair in completely unhealthy areas of the scalp. All I’m hoping for is one thing pretty much as good as Dutasteride, however with a distinct mechanism of motion.
Kintor Pharmaceutical Replace: Three Scientific Trials
Replace: August 9, 2022 — Kintor simply accomplished enrollment of 92 topics in China for Section 1 trials of its GT20029 hair loss product. This proprietary Proteolysis Concentrating on Chimera (AR-PROTAC) product is the world’s first topical androgen receptor (AR) degrader compound to enter scientific trials. They may take a look at a gel or tincture per the press launch, and outcomes can be finalized on the finish of 2022.
Replace: August 3, 2022 — Kintor simply accomplished affected person enrollment of 121 topics in its Section 2 scientific trials of KX-826 (pyrilutamide) within the US. This topical androgen receptor antagonist product can be used to deal with androgenetic alopecia.
Replace: July 2022 — The China Section 2 trial outcomes for pyrilutamide for hair loss will happen on the postponed twenty eighth Annual Assembly of the Chinese language Society of Dermatology. It runs from August 31-September 4, 2022 in Shenyang.
Updates in April 2022
Some very distinctive updates in our Kintor channel within the hair loss chat this previous week.
- Attention-grabbing new Powerpoint presentation.
- Kintor will current the outcomes of its Section 2 scientific trials (of KX-826, aka Pyrilutamide) for androgenetic alopecia at a “high-profile symposium” in June 2022.
- Some folks managed to view a categorised Section 2 outcomes slide that concluded Pyrilutamide’s hair development impact to be much like Dutasteride. This may be superb if true, since Pyrilutamide (targets the AR receptor) is completely totally different from Dutasteride (targets DHT). Anecdotal studies for now, however appear to be inflicting a whole lot of pleasure.
- Plenty of individuals are beginning to report their outcomes from utilizing KX-826 by way of a Group Purchase. I can not encourage such experimental habits, however I’m following the studies keenly. Right here is one I discovered on Reddit. Better of luck to those pioneers.
Kintor will Begin Section III Trials in China in January 2022
Within the newest replace from right this moment (November twenty fourth, 2021), Kintor Pharmaceutical introduced that it’ll start Section 3 trials in China in January 2022! Replace: Now begun.
The corporate’s IND utility for the pivotal research (section III) of pyrilutamide (KX-826) was cleared by China’s Nationwide Medical Merchandise Administration. KX-826 is the primary androgen receptor (AR) antagonist to enter section III scientific trials anyplace on the planet.
That is maybe the perfect information within the hair loss world thus far in 2021.
Replace: November 12, 2021 — Kintor Pharma simply began Section II scientific trials in ladies in China with a primary dose of pyrilutamide (KX-826). This trial pertains to androgenetic alopecia in ladies (i.e., feminine sample hair loss).
Replace: September 8, 2021 — Kintor Pharma simply introduced that its Section II scientific research for KX-826 to deal with androgenetic alopecia was a hit. Main endpoint was met. Extra detailed outcomes can be launched later per CEO Dr. Youzhi Tong. Section III scientific trials in China will start within the fourth quarter of 2021. Even higher, Section II trials are additionally at the moment happening within the US. And Section II trials for girls will happen in China
Replace: July 11, 2021 — The US FDA simply accredited Kintor’s Section II scientific trial for pyrilutamide (KX-826) to deal with androgenetic alopecia. Notice that the corporate’s trials in China are already mid-way by Section II per their pipeline web page.
They space additionally engaged on one other hair loss product named GT200029 that’s an “AR-PROTAC” compound. Its Section 1 trials will begin in China this month.
April 15, 2021
Kintor Pharma: AR Antagonist and AR Degrader
Earlier right this moment, it was introduced that Kintor obtained approval in China to start scientific trials for GT20029. This product can be in tincture or gel format, and can be examined for the therapy of androgenetic alopecia and zits.
- The GT20029 product is an androgen receptor degrader (AR Degrader). It’s developed utilizing Kintor’s proprietary Proteolysis Concentrating on Chimera (PROTAC) platform. In response to the press launch, that is the world’s first topical androgen receptor (AR) compound (AR-PROTAC) to enter scientific trials. GT20029 degrades the AR protein by way of the E3 ubiquitin ligase pathway. Throughout preclinical research, GT20029 didn’t trigger any notable unwanted side effects or systemic drug accumulation.
- Notice that Kintor’s important product for treating male sample hair loss is KX-826 (Pyrilutamide) and is an androgen receptor antagonist (AR Antagonist). I lined the latter in prior updates to this submit for those who learn until the top. KX-826 is at the moment in Section 2 scientific trials in China and in Section 1 trials within the US.
Notice that Cassiopea’s Breezula (Clascoterone) is an AR antagonist that’s effectively forward of KX-826 in the case of scientific trial stage. Kintor’s web site has a really fascinating article discussing each AR antagonist merchandise and hair loss in China basically.
Ensure to additionally learn my associated previous submit on destroying the androgen receptor to reverse hair loss.
Feb 2, 2021
Scientific Trial Standing
Kintor’s investigational new drug (IND) utility of GT20029 for androgenetic alopecia and zits vulgaris was accepted by the Nationwide Medical Merchandise Administration (NMPA) of China.
Kintor has moved ahead with its trials quicker than every other hair loss firm. I’m glad to see a Chinese language firm lastly getting into the hair loss remedy market. Scientific and technological progress appear to occur quicker in China than within the west. Hopefully, scientific trials for hair loss merchandise will comply with the identical sample.
Facet observe: In July 2020, Kintor and Utilized Biology (US) collaborated on utilizing Proxalutamide for the Therapy of COVID-19. There’s a college of thought that means anti-androgens might assist scale back Coronavirus fatalities. To this point, extra males have died from the illness then have ladies.
Under is the pipeline from Kintor’s web site:
Kintor Pharmaceutical (China) additionally lately accomplished the enrollment of 120 sufferers in its Section II scientific trials for pyrilutamide for hair loss. See the underside half of this submit for my unique dialogue on Kintor. Their inventory is traded on the Hong Kong Cling Seng Index.
Key quote from CEO Dr. Youzhi Tong:
“We are going to speed up the progress of its section II/III scientific research in order to carry advantages to the folks affected by alopecia as quickly as doable.”
Could 26, 2020
A brand new Chinese language firm named Kintor Pharmaceutical is engaged on an fascinating hair loss drug referred to as pyrilutamide . This can be very uncommon to listen to about any Chinese language firm concerned in hair loss remedy analysis. Very unusual, contemplating the nation’s speedy tempo of scientific development and big inhabitants. Furthermore, Chinese language women and men are these days balding at a lot quicker charges than up to now.
Replace: August 4, 2020 — Section Ib trials at the moment are full.
Kintor Pharmaceutical and Hair Loss
4 days in the past, China-based Kintor Pharmaceutical (also referred to as Suzhou Kintor Prescribed drugs) received important Chinese language media protection. This curiosity was associated to the corporate’s prostate most cancers, breast most cancers and hair loss medicine.
Earlier this month, Kintor Pharmaceutical additionally had a really profitable IPO in Hong Kong.
Whereas the corporate’s important focus appears to be its prostate most cancers and breast most cancers medicine, its androgenetic alopecia drug trials are additionally advancing quickly. Their important androgen receptor blocking drug candidate is known as Pyrilutamide (KX-826) and it’s utilized to the scalp topically. The corporate’s Proxalutamide drug slows or stops most cancers cell development by fully inhibiting androgens.
Pyrilutamide
The one disappointing information is that Kintor goals to tackle Johnson & Johnson’s Minoxidil. This might imply that topical Pyrilutamide is unlikely to be a lot better than Minoxidil. I hope I’m fallacious. Lately accomplished section one trials in China proved that pyrilutamide is secure and causes no main unwanted side effects in people.
Kintor is at the moment conducting section 2 scientific trials for pyrilutamide on 160 males in China, and section 1 trials on 30 males within the US. Section 3 trials on 600 folks in China, the US and Japan are deliberate for as quickly as 2021. I’d guess that the US FDA and Japanese PMDA won’t ever settle for Section 2 outcomes from China as any sort of proof to proceed to Section 3 trials within the US and Japan.
So how can the corporate proceed so quick within the US and Japan?
